Intercept Pharmaceuticals, Inc. (ICPT) Stake Raised by SG Americas Securities LLC

SG Americas Securities LLC lifted its holdings in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) by 551.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,627 shares of the biopharmaceutical company’s stock after buying an additional 10,689 shares during the quarter. SG Americas Securities LLC owned approximately 0.05% of Intercept Pharmaceuticals worth $733,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Bank of New York Mellon Corp grew its stake in Intercept Pharmaceuticals by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 77,310 shares of the biopharmaceutical company’s stock worth $4,487,000 after purchasing an additional 5,761 shares in the last quarter. Alps Advisors Inc. grew its stake in Intercept Pharmaceuticals by 9.5% in the third quarter. Alps Advisors Inc. now owns 24,720 shares of the biopharmaceutical company’s stock worth $1,435,000 after purchasing an additional 2,147 shares in the last quarter. Birchview Capital LP bought a new position in Intercept Pharmaceuticals in the third quarter worth approximately $250,000. IFP Advisors Inc grew its stake in Intercept Pharmaceuticals by 90.9% in the third quarter. IFP Advisors Inc now owns 2,482 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 1,182 shares in the last quarter. Finally, Rothschild Investment Corp IL grew its stake in Intercept Pharmaceuticals by 22.0% in the third quarter. Rothschild Investment Corp IL now owns 5,846 shares of the biopharmaceutical company’s stock worth $339,000 after purchasing an additional 1,054 shares in the last quarter. Hedge funds and other institutional investors own 73.80% of the company’s stock.

Shares of Intercept Pharmaceuticals, Inc. (ICPT) opened at $58.20 on Thursday. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 3.15. Intercept Pharmaceuticals, Inc. has a 52-week low of $54.98 and a 52-week high of $135.59.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.48) by $0.59. The business had revenue of $41.33 million for the quarter, compared to analysts’ expectations of $36.95 million. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The business’s revenue for the quarter was up 697.9% on a year-over-year basis. During the same quarter last year, the firm earned ($3.59) EPS. research analysts predict that Intercept Pharmaceuticals, Inc. will post -13.35 earnings per share for the current year.

Several brokerages recently issued reports on ICPT. ValuEngine raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Wedbush reissued an “outperform” rating and issued a $253.00 price objective on shares of Intercept Pharmaceuticals in a research note on Friday, August 25th. BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 24th. BMO Capital Markets reissued an “outperform” rating and issued a $221.00 price objective on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Finally, Robert W. Baird reissued an “outperform” rating and issued a $332.00 price objective on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $144.13.

In other news, CEO Mark Pruzanski sold 1,532 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $58.87, for a total value of $90,188.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 2,566 shares of company stock worth $151,025 in the last ninety days. Insiders own 4.50% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Intercept Pharmaceuticals, Inc. (ICPT) Stake Raised by SG Americas Securities LLC” was originally reported by Stock Observer and is the property of of Stock Observer. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.thestockobserver.com/2017/12/07/intercept-pharmaceuticals-inc-icpt-stake-raised-by-sg-americas-securities-llc.html.

Intercept Pharmaceuticals Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply